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Background: Idiopathic epilepsy is a common neurological disease in human and domestic dogs but relatively
few risk genes have been identified to date. The seizure characteristics, including focal and generalised seizures, are
similar between the two species, with gene discovery facilitated by the reduced genetic heterogeneity of purebred
dogs. We have recently identified a risk locus for idiopathic epilepsy in the Belgian Shepherd breed on a 4.4
megabase region on CFA37.
Results: We have expanded a previous study replicating the association with a combined analysis of 157 cases
and 179 controls in three additional breeds: Schipperke, Finnish Spitz and Beagle (pc = 2.9e–07, pGWAS = 1.74E-02).
A targeted resequencing of the 4.4 megabase region in twelve Belgian Shepherd cases and twelve controls with
opposite haplotypes identified 37 case-specific variants within the ADAM23 gene. Twenty-seven variants were
validated in 285 cases and 355 controls from four breeds, resulting in a strong replication of the ADAM23 locus
(praw = 2.76e–15) and the identification of a common 28 kb-risk haplotype in all four breeds. Risk haplotype was present
in frequencies of 0.49–0.7 in the breeds, suggesting that ADAM23 is a low penetrance risk gene for canine epilepsy.
Conclusions: These results implicate ADAM23 in common canine idiopathic epilepsy, although the causative variant
remains yet to be identified. ADAM23 plays a role in synaptic transmission and interacts with known epilepsy genes,
LGI1 and LGI2, and should be considered as a candidate gene for human epilepsies.
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Epilepsy is a common neurological disease in both human
and dog. Epilepsy is defined as recurrent, self-limited and
unprovoked seizures, and can be classified according to the
age of onset, the localization of seizure origin (focal or gen-
eralised), and aetiology. Epileptic seizures can be caused by
trauma or structural abnormalities of the brain, or by meta-
bolic disorders. The cause may also be directly genetic or
idiopathic (IE) [1]. It affects approximately one to five per-
cent of the human and canine populations, although it can
be five to 10 times more common in some dog breeds [2].* Correspondence: hannes.lohi@helsinki.fi
1Research Programs Unit, Molecular Neurology, University of Helsinki,
Helsinki, Finland
2Department of Veterinary Biosciences and Department of Medical Genetics,
University of Helsinki, Helsinki, Finland
Full list of author information is available at the end of the article
© 2015 Koskinen et al. This is an Open Access
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/Many human forms of epilepsy are considered to have a
genetic basis though little is known about the underlying
risk genes and variants for common forms of epilepsy des-
pite increasingly powerful methodologies [3]. Rare Mendel-
ian forms of the human disease have been associated with
many ion channel subunits, although other types of gene
pathways, related to neurodevelopment, mitochondria, and
other cellular processes, are now being identified [3].
The high prevalence of epilepsy in many dog breeds
suggests a strong genetic contribution [4] and could pro-
vide complementary resources to identify risk genes. Hu-
man and canine epilepsies share features, suggesting shared
biological aetiologies. Indeed, several orthologues have
been found in canine symptomatic recessively-inherited
epilepsies [5–12]. However, only two genes have been as-
sociated with IE to date: LGI2 in benign juvenile epilepsyarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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in the Belgian Shepherd IE [14]. Although a genetic pre-
disposition has been postulated in many breeds [4], the
identification of risk genes has been challenging. Reasons
include clinical and genetic heterogeneity and may relate
to incomplete phenotyping, underpowered study cohorts,
or incomplete resolution of the DNA marker panels.
In addition to the LGI2 mutation [13], the rare break-
through in canine IE comes from genetic studies in the
Belgian Shepherd breed. The first microsatellite-based ap-
proach suggested six loci on CFAs 2, 6, 12 and 37 [15].
Genome-wide significance was later confirmed only at
CFA37 by a low density genome-wide association study
(GWAS) and finemapping with roughly 100 cases and 100
controls [14]. A seven-fold epilepsy risk was found with
the homozygous risk haplotype in the ADAM23 locus [14].
To confirm these earlier findings and to identify possible
novel epilepsy loci, we re-genotyped a larger cohort of
Belgian Shepherds with the latest high density single-
nucleotide polymorphism (SNP) arrays and included three
other breeds with IE: Finnish Spitz, Schipperke and Beagle.
We report a shared risk in the four breeds and identify a
common risk haplotype in the ADAM23 gene by targeted
resequencing and validation. This study emphasises the
role of ADAM23 in canine epilepsy, and proposes a role
for the LGI-ADAM pathway in epilepsy across species.
Results
Epilepsy phenotypes
The seizure characteristics of idiopathic epilepsy in the
studied breeds were described based on the detailed epi-
lepsy questionnaire collected from the epileptic dogs in
each breed. The seizure characteristics of Belgian Shep-
herds and Finnish Spitz have been described recently
[14, 16] and are summarised for Schipperkes and Beagles
in Additional file 1: Results. The defining characteristics
of idiopathic epilepsy in the four breeds are presented in
Additional file 2: Table S1. Briefly, IE in the four breeds
show typical onset at early adulthood at three years of age
(range 3 months – 9 years) and manifest both focal and
generalised seizures. A high variability in seizure fre-
quency is present in all breeds ranging from one reported
episode in two years to several episodes per month. No
evidence for sex predisposition was found in Belgian
Shepherds or Schipperkes, but more affected males are re-
ported in Beagles [17] and Finnish Spitz [16].
In addition to the questionnaire reports on seizure his-
tory, clinical examinations that included complete neuro-
logical exam, blood chemistry, cerebrospinal fluid (CSF)
analyses, magnetic resonance imaging (MRI) and electro-
encephalography (EEG) were also performed in a selected
group of dogs from three of the breeds to exclude possible
external causes of seizures. None of the exams revealed ab-
normalities, whereas the EEG detected epileptic activity insome of the dogs supporting the diagnosis of IE. The clin-
ical summaries of the Finnish Spitz and Belgian Shepherd
examinations have been reported previously [14, 16]. The
clinical results of 11 epileptic and five healthy control
Schipperkes are presented in Additional file 1: Results.
Clinical studies were not performed for Beagles.
Breed-specific association studies
A total of 591 dogs in the four breeds were genotyped with
the high-density SNP arrays. They formed distinct genetic
populations according to the multidimensional scaling
(MDS) plot drawn from the two top principal compo-
nents of genetic variation (Additional file 3: Figure S1A).
In Belgian Shepherds with two breed variants Groenendael
(n = 118) and Tervueren (n = 137), 93 cases and 162 con-
trols passed the diagnostic and genotype quality control
criteria. This cohort is largely new having only 16 % over-
lap with our previous study that used the lower dens-
ity arrays [14]. The breed variants are closely related but
represent separate clusters in the MDS plot (Additional
file 3: Figure S1B). The genomic inflation factor λ was
0.81. GWAS analysis revealed only one genome-widely
significant locus, confirming the previously identified
association on CFA37 at 14.5–17.5 Mb with the best asso-
ciated SNP BICF2P1131874 at 15111724 bp (praw = 3.57E–
08, pGWAS = 3.78E–03) (Additional file 4: Figure S2A).
The Schipperke cohort with 67 IE cases and 70 con-
trols formed a single population in the MDS plot analysis
(Additional file 3: Figure S1C) as expected since the major-
ity of the dogs came from one large pedigree (Additional
file 5: Figure S3). Despite correcting for the relatedness
using mixed model approach, no significant association
was revealed in the GWAS (Additional file 4: Figure S2B).
The genomic inflation factor λ was 0.85.
The Finnish Spitz cohort including 61 cases and 68
controls, clustered together in the MDS plot (Additional
file 3: Figure S1D). GWAS did not reveal any significant
association (Additional file 4: Figure S2C). The genomic
inflation factor λ was 0.81.
The Beagle cohort consisted of 29 IE cases and 41 con-
trols and represented two clearly separate genetic popula-
tions in the MDS plot (Additional file 3: Figure S1E). The
Beagle samples originated from Finland (60 %), Germany
(30 %) and Sweden (10 %). Most of the Finnish dogs clus-
tered separately from the German dogs, although some
overlap was present. Three Finnish and four Swedish
Beagles clustered together with the German Beagles, and
three Swedish Beagles clustered together with the Finnish
Beagles. The majority of the Finnish Beagles belonged to
the Finnish hunting line, which has been maintained sep-
arately from other Beagles to maintain the hunting skills.
The two genetic subpopulations seen in the MDS plot
represent this population substructure (Additional file 3:
Figure S1E). GWAS revealed no significant association in
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pendent analysis of the German and Finnish hunting lines
(data not shown). The genomic inflation factor λ was 0.81.
Across breed GWAS
The GWAS data from the four breeds were analysed
jointly for possible common risk variants. An intronic
SNP BICF2P1131874 in the ADAM23 gene on CFA37 at
15111724 bp showed the strongest association signal
(praw = 1.04e–11, pGWAS = 6.17e–07, λ 0.87) (Fig. 1a,
Additional file 4: Figure S2E). When the combined data
were analysed without Belgian Shepherds, another in-
tronic SNP in the ADAM23 gene showed strong associ-
ation (BICF2P1290526 at 15093174 bp, pc = 2.93e–07,
pGWAS = 1.74e–02, λ 1.11) (Additional file 4: Figure S2F).
These results suggest a shared risk locus exists across
the four breeds.
Targeted resequencing of the ADAM23 locus in Belgian
Shepherds
Our two GWAS experiments in Belgian Shepherds (the
present and the previous study) support the strongest asso-
ciation within the ADAM23 gene. Therefore, we selected
the two highest associated risk variants within ADAM23 toFig. 1 Genome-wide association study across four breeds and gene conten
including Belgian Shepherds, Schipperkes, Finnish Spitz, and Beagles highl
association with IE are located in the ADAM23 gene. The red line indic
content of the 4.4 Mb critical region on CFA37, which was targeted and reseq
and annotation gaps in the CanFam3.1 referencedefine the risk haplotype for 12 IE cases and 12 controls
with opposite homozygous haplotypes. A 4.4 Mb region
spanning ADAM23 was captured and resequenced. Rese-
quencing data of CFA37 was of high quality with an aver-
age 100x sequence coverage in each sample in the target
region (Additional file 6: Table S2, Fig. 1b). In total, 5934–
9463 single-nucleotide variants (SNVs) and 2922–4206
insertion-deletion variants (indels) were identified in each
dog (Additional file 6: Table S2).
However, only 37 variants showed opposite genotypes
in the risk and non-risk haplotypes, including 29 SNVs
and eight indels unique to all 12 cases. These 37 vari-
ants cover a 96 kb interval within ADAM23 (15085438–
1518443 bp). These variants included one coding variant
(c.1159G > A, p. R387H at 15113940 bp) that was identi-
fied in our previous Sanger sequencing experiment and
was used to define the risk haplotype [14]. All the other
variants identified were intronic to ADAM23 with 13
known variants from dbSNP.
Validation reveals a shared six-variant risk haplotype
across breeds
We prioritised 25 of the 37 variants discovered in resequen-
cing for a validation in a larger cohort using conservationt of the associated locus on CFA37. a. Genome-wide association study
ights a single locus on CFA37. The SNPs showing the strongest
ates genome-wide significance level of p-values. b. The UCSC-based gene
uenced. The figure also includes the genotyped HD markers in the locus
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(Additional file 7: Table S3). These 25 variants included
one coding variant (c.1159G > A, p. R387H, 15113940 bp)
and 24 intronic variants in ADAM23. In addition, we
added a second coding variant (c. 1158C > T, p. R387C,
15113939 bp), which is rare in Belgian Shepherds, but
was detected in sequencing samples from other breeds in
our previous study (unpublished result) [14]. ADAM23
intronic variant BICF2P1290526 (at 15093174 bp) was
included in the validation, as it showed the strongest as-
sociation signal in the combined GWAS without Belgian
Shepherds. In total, 27 variants were genotyped in 640
dogs across four breeds (Belgian Shepherds, Schipperkes,
Finnish Spitz and Beagles). One variant appeared mono-
morphic (15181443 bp) and was excluded from further
analyses.
The genotyping data was analysed for association in in-
dividual breeds and all breeds combined. We found that
the coding variant (c.1159G > A, p. R387H) was associ-
ated with IE in Belgian Shepherds (praw = 2.59e–11) and
Finnish hunting Beagles (praw = 0.008), but not in German
Beagles (praw = 0.95), Schipperkes (praw = 0.98) or Finnish
Spitz (praw = 0.98) (Additional file 7: Table S3). The second
coding variant (c.1158C > T, p. R387C) was associated
with IE in Schipperkes (praw = 0.005) and Finnish Spitzs
(praw = 0.05), but not in Finnish (praw = 0.98) or German
Beagles (praw = 0.60), or Belgian Shepherds (praw = 0.2).
The minor allele (T) frequency was only 0.006 in Belgian
Shepherds (Additional file 7: Table S3).
A majority of the intronic SNPs showed significant asso-
ciations in individual breeds (Additional file 7: Table S3).
In the combined analysis of all four breeds, intronic
variants both upstream and downstream of exon 12
showed strong association with the lowest p-value at
15113325 bp (pcmh = 2.76e–15, OR 2.93, 95 % CI 2.23–
3.85) (Fig. 2b; Additional file 7: Table S3).
Haplotype analysis using Haploview indicated a strong
linkage disequilibrium between the 26 variants (Fig. 2c)
defining a risk haplotype that spanned almost the whole
genotyped region (~96 kb) in each breed. The risk hap-
lotypes were similar but not identical across breeds.
Breed-wise comparisons revealed a shared 28-kb six-
variant risk haplotype (T-C-del-del-G-G) encompassing
the exons 5–11 of ADAM23 between 15085438 and
15113325 bp (Table 1). Dogs homozygous for the risk
haplotype had the highest risk of epilepsy with OR vary-
ing from 3.33 to 12 across associated (p < 0.05) breeds
(Table 1). For the four breeds having a significant risk
haplotype, fewer than 10 % of cases did not carry that
risk haplotype.
Uncovering the missing upstream sequence for ADAM23
In the absence of a compelling causative variant in the
coding region of ADAM23, we hypothesised that thevariant was in the regulatory region of the gene. How-
ever, the dog reference sequence (CanFam3.1) has a gap
of unknown size in the regulatory region upstream of
exon 1 of the ADAM23 gene (Additional file 8: Figure S4).
Additionally, the sequence in the 5’ end of the ADAM23
gene, including exon 1, is highly GC-rich (>80 %), challen-
ging conventional mutation screening. For example, there
is a 6-bp sequence (CCCCTG) repeated seven times
immediately upstream of exon 1 (Additional file 8: Figure S4).
To enable efficient study of this 5’ regulatory region,
we aimed to fill the gap using a BAC clone from the
target region and PacBio sequencing technology. We
found a 190-bp GC-rich (87 %) sequence with simple
repetitive elements that has expanded the canine refer-
ence sequence for this gene (Additional file 8: Figure S4).
This 5’ region upstream of exon 1 could not be in-
cluded in the capture design and while exon 1 was in-
cluded in the design, it did not work in the capture
experiment, possibly due to the very high GC-content of
the region (Fig. 2a).
Discussion
This study significantly expands from our previous IE stud-
ies in Belgian Shepherds [14, 15] to achieve four major
goals. First, we sought to confirm the association at CFA37
and possibly reveal other loci by replicating our original
low resolution study using high resolution GWAS in a lar-
ger independent cohort. Second, we assessed three other
IE breeds (Schipperke, Finnish Spitz, and Beagle) with rea-
sonable sample size by GWAS to map new IE loci. Third,
we undertook a combined analysis of the data for the four
breeds to identify shared IE loci. Finally, we aimed to refine
the associated region and identify causative variants by tar-
geted resequencing.
Our findings provide strong genetic evidence for the
role of ADAM23 in canine IE. The Belgian Shepherd data
with increased resolution and sample size confirmed the
association to ADAM23 on CFA37 but did not reveal
new loci at a genome-wide significant level. A combined
analysis of the three other breeds using high resolution
GWAS also highlighted the ADAM23 gene though breed-
specific associations were not revealed. Our previous at-
tempt to demonstrate the ADAM23 locus involvement in
those breeds [14] failed because the selected SNPs were
uninformative to detect association in these breeds. Our
targeted resequencing of the large 4.4 Mb locus uncovered
a set of new case-specific variants found only in the
ADAM23 gene, and a replication study with those variants
revealed a strongly associated shared risk haplotype in all
four breeds. The 28-kb risk haplotype consisting of in-
tronic variants lies in the middle of the ADAM23 gene.
These results implicate ADAM23 in IE and suggest that
the causative variant (s) yet to be found resides within the
risk haplotype or adjacent to the gene outside the coding
Table 1 Haplotype analysis revealed a common risk haplotype for idiopathic epilepsy. A risk haplotype shared between the breeds
was identified between 15085438 and 15113325 bp on CFA37. It consisted of alleles T-C-del-del-G-G at 15085438, 15106446,
15108593, 15108802, 15111724 and 15113325 bp in ADAM23
Breed Risk haplo
freq. cases
Risk haplo
freq. controls
p-value OR (95 % C.I.) P-value
(homozygosity)
OR (95 % C.I.)
(homozygosity)
Cases/controls without
risk haplotype
Belgian Shepherd 0.75 0.49 4.3e–11 3.2 (2.3–4.6) 4.1e–10 4.6 (2.8–7.6) 10 %/28 %
Schipperke 0.81 0.65 0.003 2.3 (1.3–4.0) 0.0006 3.3 (1.7–6.7) 6 %/9 %
Finnish Spitz 0.89 0.67 1.6e–05 4.1 (2.1–8.2) 4.9e–05 4.9 (2.2–10.8) 2 %/12 %
Beagle (Finnish hunting) 0.96 0.7 0.006 11.5 (1.4–93.1) 0.009 12 (1.4–106.2) 0 %/12 %
Beagle (German) 0.63 0.65 0.9 0.9 (0.3–2.6) 0.9 1.1 (0.3–4.6) 19 %/13 %
haplo freq haplotype frequency, OR odds ratio, C.I. confidence interval
Fig. 2 The variants identified in the resequencing and associated with idiopathic epilepsy are located in ADAM23. a. The 37 case-specific variants
identified in Belgian Shepherds by targeted resequencing were located within a 39-kb region of ADAM23 and span exons 5–17 highlighted with
blue. The entire ADAM23 region spanning 14,970,211–15,175,391 bp on CFA37 based on the UCSC Genome Browser on dog (CanFam3.1). Thirteen
Illumina HD markers are within the ADAM23 gene, and four within the 39-kb region. There is a gap in the reference sequence in the 5’ end ADAM23,
and the exon 1 sequence has high GC content. b. Association results of the 26 variants at the target region on CFA37 in Belgian Shepherds,
Schipperkes, Finnish Spitzs, Beagles (Finnish hunting and German sub-populations), and combined data. The coding variants at 15113939
and 15113940 bp show inconsistent association between the breeds. c. There is strong linkage disequilibrium in the ADAM23 gene region
in the four associated breeds: (i) Belgian Shepherds, (ii) Schipperkes, (iii) Finnish Spitzs and (iv) hunting Beagles from Finland. The most consistent
association across breeds was identified for a six-variant risk haplotype spanning a 28-kb region containing exons 5–11 outlined with black
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amino acid in exon 12 of the ADAM23 gene show con-
flicting association in the studied breeds suggesting this is
not the causal mutation. The sequence gap at the 5’ region
of ADAM23 and poor resequencing coverage in the
GC-rich exon 1 did not permit definitive assessment of
the 5’ regulatory region of the gene. We did however, un-
cover the 190 bp sequence gap immediately upstream
of ADAM23 in a BAC clone. This will help the future
characterization of the role of the 5’ regulatory region in
canine IE.
While most affected dogs carried the risk haplotype, it
was also commonly found in control dogs with frequen-
cies of 0.49 to 0.70 depending on the breed. These results
suggest a low penetrance of the seizure predisposing vari-
ant in ADAM23. The high frequency of the risk haplotype
combined with low penetrance may partly explain why IE
is so common in many dog breeds despite active preven-
tion efforts in the breeding programs. Accurate estimation
of penetrance may be adversely affected by imperfect diag-
nosis of mild cases that are now in the control group.
Identification of the causative variant (s) will permit more
precise estimations in future experiments.
ADAM23 is an excellent candidate gene for IE. It inter-
acts with known IE genes, LGI1 and LGI2 [13, 18, 19]. A
truncating mutation in the LGI2 gene prevents its secre-
tion in neurons and causes recessively inherited benign ju-
venile epilepsy in the Lagotto Romagnolo breed [13]. LGI2
is a paralog of LGI1 which is the causal gene for ADTLE/
ADPEAF (autosomal-dominant temporal lobe epilepsy/
autosomal dominant partial epilepsy with auditory fea-
tures, MIM# 600512), a non-remitting epilepsy in humans
with onset typically in adolescence or early adulthood
[20]. Both LGI1 and LGI2 are neuronally secreted pro-
teins [21], and interact with ADAM neuronal membrane
proteins, such as ADAM11, ADAM22 (post-synaptic) and
ADAM23 (pre-synaptic) [18]. ADAM23 is expressed in
the central nervous system, and high expression levels
have been detected in the cerebral cortex pyramidal cells
and in the CA1 and CA3 pyramidal cells of the hippocam-
pus, as well as in the cerebellar Purkinje cells [18, 22, 23].
ADAM23 is the primary receptor for LGI1, and needed
for LGI1-mediated dendritic branching [23]. The func-
tion of the ADAM23-LGI2 complexes is currently be-
ing studied.
A complete knockout of ADAM23 in mice results in
ataxia, tonic-clonic seizures, failure to thrive and death
within two weeks from birth [23, 24]. Heterozygous mice
appear otherwise normal but have a lower seizure thresh-
old [23]. A reduction in the ADAM23-mediated LGI1-
stimulation of neurite outgrowth in the central nervous
system was suggested to contribute to epilepsy, although
other yet unknown ADAM-LGI-mediated alterations may
exist [23].Conclusions
Our genetic data implicates ADAM23 as a common risk
gene for idiopathic epilepsy in four unrelated dog breeds
and further replication studies in additional breeds are on-
going. Our data suggest causal variation with low penetrance
in the regulatory region of the gene. The identification of
the causal variation (s) and further functional studies are
warranted to improve the understanding of the ADAM23-
mediated molecular mechanisms in the brain and their
role in seizure susceptibility.
Methods
Sample collection and phenotyping
Whole blood samples were collected from privately owned
dogs with the owner’s consent mainly from Finland but
also from USA, Germany, Sweden, Poland, Switzerland
and Australia. Buccal swab samples were collected from
108 Belgian Shepherds from USA and four Schipperkes
from UK. The samples were recruited through breed
clubs, scientific collaborators, veterinarians, and advertise-
ment in various dog fancier forums. The samples were
stored at the Dog DNA bank at the University of Helsinki
along with the dogs’ health and pedigree information. Col-
lection of samples was approved by the Animal Ethics
Committee at the State Provincial Office of Southern Finland
(ESLH-2009-07827/Ym-23 and ESAVI/6054/04.10.03/2012)
or by the University of California, Davis Institutional Animal
Care and Use Committee.
The diagnosis of idiopathic epilepsy was based on a
10-page epilepsy questionnaire available in multiple lan-
guages [25]. The questionnaire was required from all dogs
with owner-reported seizures unless sufficient information
was available through phone or e-mail interviews with the
dog owner, or dog health information updates to the re-
search group by the dog owner. The diagnosis was estab-
lished by the following criteria: at least two seizure episodes
at least two months apart, no other known conditions or
events which could predispose to seizures (e.g., untreated
metabolic diseases, brain tumours, head trauma, or intoxi-
cation), age of onset between six months and five years.
Dogs with lower or higher age of onset were included if
findings in general clinical and neurological examination,
complete blood count, blood biochemistry and MRI sup-
ported the diagnosis of IE.
The control dogs were older than seven years of age
and had never had epileptic seizures or other owner re-
ported chronic diseases. The health status of the control
dogs was confirmed by contacting the owner by phone,
e-mail or mail. The controls were matched to the cases
according to breed, breed variant, and country of origin.
A large proportion of the Schipperke cohort consisted
of a pedigree of closely related individuals, including
concordant and discordant sibling pairs, their parents,
grandparents, half siblings, but also few unrelated cases
Table 2 The number of samples included in the genome-wide
association study (GWAS) and the validation of the variants on
CFA37
Breed GWAS CFA37 target region
finemapping
Cases Controls Cases Controls
Belgian Shepherd 93 162 127 176
Groenendael 57 61 73 66
Tervueren 36 101 54 110
Schipperke 67 70 68 70
Finnish Spitz 61 68 61 68
Beagle 29 41 29 41
German subpopulation 15 16 15 16
Finnish hunting line 14 25 14 25
Total 250 341 285 355
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Additional file 5: Figure S3.
Clinical examination
Eighteen Schipperkes (11 cases, five controls and two
with unknown status) were clinically studied including
general clinical and neurological examination, complete
blood count, blood biochemistry, 20-min interictal EEG,
MRI, and CSF analysis. The clinical studies were per-
formed at the Referral Animal Neurology Hospital Aisti,
Vantaa, Finland as previously described [14, 16].
DNA extraction
Genomic DNA was extracted from the whole blood
samples and buccal swabs of four Schipperkes using
the Puregene DNA Purification Kit (Gentra Systems)
or Chemagic Magnetic Separation Module I (Chemagen
Biopolymer-Technologie AG, Baeswieler, Germany) ac-
cording to the manufacturer’s instructions. The Qiagen
DNA Blood Mini Kit (QIAGEN Inc., Valencia, CA) was
used for a portion of the Belgian Shepherd samples from
the US [26]. The remaining Belgian Shepherd DNA sam-
ples from the US were extracted from buccal swabs as pre-
viously reported [27].
Power analysis
To replicate the previous findings in Belgian Shepherds
on CFA37, we estimated the required sample size using
the Genetic Power Calculator [28]. The parameters used
in the calculations were derived from our previous art-
icle [14]: high risk allele frequency and marker allele fre-
quency 0.49, disease prevalence 0.10, genotypic relative
risk Aa 3, genotypic relative risk AA 5, and D’ 0.8. To
have an 80 % power with 0.05 significance level in case–
control allelic 1 df test, 77 cases were needed. The statis-
tical power of our study materials were as follows:
Schipperkes 0.72, Finnish Spitz 0.67, Beagles (total) 0.46,
Beagles (Finnish hunting subpopulation) 0.29, and Beagles
(German subpopulation) 0.23. The statistical power in the
whole replication material was 0.98.
Genome-wide association study
A total of 591 dogs were included in the genome-wide ana-
lyses from 4 dog breeds: Belgian Shepherd (Groenendael
and Tervueren), Schipperke, Finnish Spitz, and Beagle,
and 640 dogs were included in the finemapping of the
ADAM23 locus. The Belgian Shepherd sample cohort used
had a 16 % overlap with the samples used in our previ-
ously published study [14]. The GWAS and finemapping
cohort were mainly overlapping with each other. The
Belgian Shepherd cohort included in the finemapping ef-
fort partially overlapped with the cohort used in our previ-
ous study [14]. The number of samples from each breed is
presented in Table 2.The samples were genotyped with the Illumina Canine
HD Bead chips (Illumina, Inc., San Diego, CA, USA) for
more than 173,000 SNPs across all canine chromosomes.
The Beagle, Schipperke, and Finnish Spitz samples were
genotyped at the Centre National de Génotypage (Paris,
France) as part of the EU-funded LUPA project [29], and
the Belgian Shepherd samples were genotyped at GeneSeek
(Lincoln, NE, USA). The genotype data was analysed with
GenABEL v. 1.6–7 [30] in R v. 2.13.0. The chromo-
somal positions of the SNPs were based on the CanFam3.1
build. The data was filtered for minor allele frequency >
0.05, genotype call rate > 0.95, individual call rate > 0.95
and Hardy-Weinberg equilibrium p > 0.0001 in the con-
trols. MDS plots were produced for each genotyped breed
to identify outliers and population stratification. Identity-
by-state values were calculated for each pair of individuals
to control for duplicate samples and known related-
ness. The GWAS were performed using mixed model
approach in GenABEL [30, 31]. Mixed models test was
selected because it corrects for the relatedness between
the genotyped individuals. The estimation of polygenic
model was performed using the polygenic option in
GenABEL [32]. If the genomic inflation factor λ was >1,
corrected association p-values were used. In addition,
association p-values were adjusted using Bonferroni cor-
rection to control for multiple testing by multiplying the
association p-values by the number of SNPs included in
the analyses.
The quality control and GWAS were performed separ-
ately for each breed. For breeds with more than one breed
variant or line, the GWAS analyses were performed using
the variant or line as strata, and the analyses were also
performed separately in each variant or line. Combined
analysis of all four breeds was performed using breed as
strata.
Koskinen et al. BMC Genomics  (2015) 16:465 Page 8 of 10Targeted resequencing in Belgian Shepherds
A 4.4 Mb locus on CFA37 was selected for a sequence
capture and resequencing experiment (Fig. 1b). We se-
lected 12 Belgian Shepherd cases and 12 healthy Belgian
Shepherd controls homozygous with respect to the risk-
and non-risk haplotypes based on our previous GWAS
results [14]. The risk and non-risk haplotypes were de-
fined based on the alleles for BICF2P890779/rs24025367
at 15124213 bp, and a p. R387H (c. 1159G > A) variant in
ADAM23 exon 12 at 15113940 bp. The mutation nomen-
clature is based on GenBank accession XM_844759.3
(ADAM23) with nucleotide one being the first nucleotide
of the translation initiation codon ATG. The region be-
tween 13,250,000 and 17,612,000 bp on CFA37 was selected
for the sequence capture, because it contains the associated
locus. There is a gap in the 5’ end of the ADAM23 gene,
and this region was thus excluded from this original se-
quence capture design. The 5’ region was sequenced using
a BAC clone (see PacBio method below). The SeqCap
EZ Developer Library capture assays were designed by
Roche-Nimblegen (Madison, WI, USA) for the CanFam3.1
build, and the in-solution sequence capture and paired-end
sequencing were performed at the Institute for Molecular
Medicine Finland (FIMM) Sequencing facility (Helsinki,
Finland). The sequencing was performed with the HiSeq2000
instrument (Illumina, Inc., San Diego, CA, USA).
The data was analysed with a custom-developed bio-
informatics pipeline [33]. On average, 8523875 paired-
end reads were generated with read lengths of 93 bp for
each sample. Quality check was performed on the raw data
with FASTX-Toolkit [34] to remove the bases incorrectly
called by the sequencing machine. For this, base pairs
below a base call accuracy of 99 % i.e., bases with Phred
scores <Q20 were trimmed to decrease false-positive vari-
ants during variant calling. The quality controlled paired-
end reads were aligned to the canine reference genome
(CanFam.3.1) using BWA v. 0.6.1 alignment tool with
default parameters [35]. An average of 95.75 % of the
reads were mapped to the reference genome for each
sequenced sample. After mapping, the reads that mapped
to the targeted region were extracted followed by the re-
moval of potential PCR duplicate reads using SAMtools v.
0.1.18 [36]. This has retained an average of 50.75 %
of the reads mapped in the targeted region of 4 Mb
on CFA37.
Fold coverage for each base in the target region was
calculated using unique reads. The average coverage for
each sample in the target region was 100-fold. Less than
1.5 % of the targeted bases were not covered with at least
one read whereas 83 % of the targeted bases were covered
with at least 50X coverage, which signifies the high quality
of the data. A region between 14996848 and 14997400 bp,
spanning exon 1 of the ADAM23 gene was not covered
in any of the samples. Coverage statistics for all thesequenced samples were calculated using GATK v. 2.1-12-
ga99c19d [37, 38].
Local Realignment around potential insertion-deletion
sites and base quality scores recalibration were imple-
mented using GATK [37, 38] and fix mate-pair informa-
tion using SAMtools [36] to improve the quality of the
sequence data before variant calling. We aimed for max-
imum sensitivity to detect variants in the targeted region
and therefore considered the union of variant calls from
two variant calling algorithms; SAMtools [36] and GATK
[37, 38]. In total, we identified an average of 7955 SNPs and
3650 indels in each sample (Additional file 6: Table S2).
The identified variants were compared to the NCBI SNP
database (dbSNP build 131). On average, 18 % of the vari-
ants were known, and 82 % were novel in each sample.
Furthermore, variants were annotated to the Ensembl
gene set to find the location in the reference genome using
ANNOVAR [39].
Thirty-seven variants (29 SNVs, eight short indels) with
opposite genotypes in the individuals with the risk-and
non-risk haplotypes were identified from the data for fur-
ther validation (Additional file 9: Table S4). The variants
were confirmed by visual inspection of the reads and vari-
ant calls with the Integrative Genomics Viewer [40, 41].
PacBio sequencing
A BAC clone CHORI82_R4_266G10, which spans the
genomic region of ADAM23 on CFA37 (at 14898298–
15055982 bp) was sequenced using PacBio sequencing
technology (Pacific Biosciences, Menlo Park, CA, USA)
at DNA Sequencing and Genomics laboratory, Institute of
Biotechnology, University of Helsinki, Finland. The BAC
clone was provided by The BACPAC Resource Center
(BPRC) (Children’s Hospital Oakland Research Institute,
Oakland, California, USA) in DH10B E. Coli host. The
clone was amplified and cultured according to the pro-
vider. BAC clone DNA was extracted with the QIAGEN
Large-Construct Kit (Qiagen, Hilden, Germany). The clone
(25 μg DNA) was sequenced using the PacBio RS se-
quencing platform using P5 polymerase and C3 chemistry
(P5-C3). Total of 529.8 Mbp PacBio reads were assembled
using HGAP.3 (Hierarhical Genome Assembly Process)
implemented in SMRT Analysis. The complete circular
BAC clone, in length of 212 184 bp, was sequenced at
2200x coverage.
Validation and haplotype analysis
Twenty-five case-specific variants (20 SNVs and five
indels) identified in the resequencing were selected for
validation in larger sample sets (Table 2, Additional file 9:
Table S4). Variants with high conservations scores were
prioritized for validation. The conservation was evaluated
through GERP scores [42] obtained from Ensembl [43],
and PhastCons and Phylop scores available through UCSC
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cluded in the genotyping: BICF2P1290526 at 15093174 bp
which showed the strongest association signal in the
ADAM23 gene in the combined GWAS without Belgian
Shepherds, and the p. R387C (c. 1158C > T) variant at
15113939 bp in exon 12 of ADAM23 which we had iden-
tified in our previous Sanger sequencing experiments (un-
published result) [14]. Thus, a total of 27 variants were
included in the validation.
A Sequenom iPlex Gold (Sequenom, Inc, San Diego, CA,
USA) experiment was designed for 21 variants (Additional
file 9: Table S4). Six additional variants were genotyped by
Sanger sequencing because they did not fit in the iPlex
pool. A total of 640 samples from four dog breeds were
included in the validation experiment based on the asso-
ciation results on CFA37 in the GWAS (Table 2). The
Sequenom experiment was designed and the genotyping
with the MALDI-TOF mass spectrometer were performed
at FIMM Technology Centre (Helsinki, Finland), and
yielded a 100 % call rate. The accuracy of the genotypes
was controlled by using duplicate samples on each plate,
and checking for Mendelian inconsistencies when pos-
sible. The Sanger sequencing was performed using stand-
ard protocols. Sequencing was carried out at the FIMM
Technology Centre (Helsinki, Finland) and the genotypes
were determined using Sequencher 5.1 sequence analysis
software (Gene Codes Corporation, Ann Arbor, MI, USA).
The genotypes were analysed for association using PLINK
v. 1.07 options for chisq test for allelic and genotypic asso-
ciations [46, 47]. The haplotype blocks were deter-
mined with Haploview [48]. The analyses were done for
each breed and breed variant or line separately. Combined
association analysis was performed using the Cochran-
Mantel-Haenzel-test to control for the differences in the
odds ratios between breed clusters. The six-variant haplo-
types for each individual were estimated using PLINK v.
1.07 [46, 47].
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